Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 3,828 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 3,828 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $18.10, for a total transaction of $69,286.80. Following the completion of the sale, the chief operating officer directly owned 210,164 shares in the company, valued at approximately $3,803,968.40. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.02, for a total transaction of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.68, for a total transaction of $233,500.00.
• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.05, for a total transaction of $225,625.00.

Bicara Therapeutics Price Performance

BCAX opened at $16.42 on Tuesday. The firm has a market capitalization of $899.49 million, a P/E ratio of -7.33 and a beta of -0.79. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71. The company has a fifty day moving average price of $17.47 and a 200-day moving average price of $14.77.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). On average, analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its stake in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the period. Invesco Ltd. lifted its position in Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $45,000. Finally, Avanza Fonder AB boosted its stake in shares of Bicara Therapeutics by 42.7% during the third quarter. Avanza Fonder AB now owns 9,371 shares of the company’s stock valued at $148,000 after purchasing an additional 2,804 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BCAX. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company raised their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Mizuho upgraded Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.